{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"34"}],"units":"Participants"}],"description":"Number of participants with treatment-related adverse events as assessed by CTCAE v.4.0","groups":[{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle.\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG000","title":"Dose Regimen A (DR-A) PTCL Expansion"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 3 and 5 of a 21-day cycle\n\nALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG001","title":"Dose Regimen C (DR-C) PTCL Expansion"},{"description":"Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle Drug: Palbociclib Fixed-dose capsule administered orally on days 1 through 21 of a 28-day cycle ALRN-6924: ALRN-6924 will be administered as an IV infusion","id":"OG002","title":"Combination With Palbociclib Expansion (DR-A)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From Day 1 of treatment until 30 days after the last cycle of treatment (each cycle in DR-A is 28 days, DR-B and DR-C is 21 days), an average of 138 Days","title":"Evaluate the Safety and Tolerability of ALRN-6924 in Adult Patients With Advanced Solid Tumors or Lymphomas With Wild-type (WT) TP53 Who Are Refractory to or Intolerant of Standard Therapy, or for Whom no Standard Therapy Exists, Expansion","type":"PRIMARY","unitOfMeasure":"Participants"}